DECAMP-2
Detection of Early Lung Cancer Among Military Personnel Study 2 (DECAMP-2): Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
Sponsor study identifier
observational
665
1 country
15
Study Start
September 2011
Actual (reported)Primary Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this project is to improve lung cancer screening in high-risk individuals by identifying biomarkers of preclinical disease and disease risk that are measured in minimally invasive and non-invasive biospecimens. Existing biomarkers for lung cancer diagnosis as well as new biomarkers discovered specifically in this clinical setting will be examined. Biomarkers that identify individuals at highest risk for being diagnosed with lung cancer prior to the appearance of concerning symptoms could increase the utility of lung cancer surveillance and the efficiency of lung cancer chemoprevention clinical trials. Achieving these goals would improve the detection and treatment of early stage and incipient lung cancer, while restricting the risk of these procedures to those individuals who currently exhibit the early molecular warning signs of impending disease.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2011
Actual (reported)May 27, 2014
Actual (reported)July 22, 2015
Actual (reported)December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Lung Cancer
Four years
For this longitudinal screening cohort, we will enroll 800 participants who currently or historically smoked and who have a 10 year Bach risk model of lung cancer \> 2.5% (5). We will include participants 50 to 79 years old, with ≥10 cigarettes/day for current smokers, or ≥20 pack years for former smoker who quit 20 years ago or less. In order to further enrich for lung cancer risk, participants also will have COPD/emphysema or at least one first-degree relative with a diagnosis of lung cancer. We will exclude patients previously diagnosed with lung cancer. These patients will be followed for a total of 4 years with annual follow-up visits. Biosamples from airway and blood and images will be collected.
Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Military personnel
Regents of the University of California LA (Los Angeles VA Healthcare System)
Los Angeles, California, 90073, United States
University of California Los Angeles Medical Center
Los Angeles, California, 90095, United States
Naval Medical Center San Diego
San Diego, California, 92134, United States
Denver Research Institute
Denver, Colorado, 80220, United States
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889, United States
Boston University Medical Center
Boston, Massachusetts, 02118, United States
Boston VA Research Institute, Inc
Billatos E, Ash SY, Duan F, Xu K, Romanoff J, Marques H, Moses E, Han MK, Regan EA, Bowler RP, Mason SE, Doyle TJ, San Jose Estepar R, Rosas IO, Ross JC, Xiao X, Liu H, Liu G, Sukumar G, Wilkerson M, Dalgard C, Stevenson C, Whitney D, Aberle D, Spira A, San Jose Estepar R, Lenburg ME, Washko GR; DECAMP and COPDGene Investigators. Distinguishing Smoking-Related Lung Disease Phenotypes Via Imaging and Molecular Features. Chest. 2021 Feb;159(2):549-563. doi: 10.1016/j.chest.2020.08.2115. Epub 2020 Sep 16.
Billatos E, Duan F, Moses E, Marques H, Mahon I, Dymond L, Apgar C, Aberle D, Washko G, Spira A; DECAMP investigators. Detection of early lung cancer among military personnel (DECAMP) consortium: study protocols. BMC Pulm Med. 2019 Mar 7;19(1):59. doi: 10.1186/s12890-019-0825-7.
Blood, Urine, Sputum, Nasal brushing, Buccal scraping, Bronchial Biopsy, Bronchial brushing, lung tissue
Ehab Billatos, MD
Boston University
Denise Aberle, MD
University of California, Los Angeles
665 participants (actual enrollment reported by the registry).
First Submitted
May 27, 2014
First Posted
July 22, 2015
Study Start
September 2011
Actual (reported)Study to Assess Stairs as an Outcome Measure in Individuals With Pulmonary Disease
Contact the study team to confirm eligibility.
Boston, Massachusetts, 02132, United States
Health Research Inc. Roswell Park Division
Buffalo, New York, 14263, United States
Trustees of University of Pennsylvania (Philadelphia VA Medical Center)
Philadelphia, Pennsylvania, 19104, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Veterans Research Foundation of Pittsburgh
Pittsburgh, Pennsylvania, 14520, United States
Middle Tennessee Research Institute (Vanderbilt University)
Nashville, Tennessee, 37212, United States
Dallas VA Research Corporation
Dallas, Texas, 75216, United States
San Antonio Military Medical Center
San Antonio, Texas, 78219, United States
Naval Medical Center Portsmouth
Portsmouth, Virginia, 23708, United States
Primary Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
April 1, 2026
Record last verified: 2026-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: